论文部分内容阅读
目的探讨动机性访谈(motivational interviewing,MI)对肺癌化学疗法(化疗)初治患者焦虑抑郁情绪的影响。方法选择2015年5月—2016年4月收治的于术后转入科室接受治疗的肺癌化疗初治患者,并使用数字随机表法将纳入患者分为MI组和对照组。对照组给予常规护理,包括健康教育、心理护理、院外随访;MI组在常规护理基础上给予3次动机访谈和1次电话随访干预患者焦虑抑郁情绪。两组患者在入院时、化疗后1个月分别采用焦虑自评量表(Self-rating Anxiety Scale,SAS)、抑郁自评量表(Self-rating Depression Scale,SDS)和汉化版的心理痛苦温度计(Distress Thermometer,DT)进行评估。结果入院时,两组患者的SAS、SDS及DT得分差异无统计学意义(P>0.05)。化疗后1个月,MI组SAS、SDS及DT得分较入院时有所缓解,差异有统计学意义(P<0.05);MI组与同期对照组的SAS、SDS、DT评分比较,差异有统计学意义(P<0.05)。结论 MI可改善肺癌化疗初治患者的焦虑抑郁情绪,为临床医护人员干预肺癌化疗初治患者的不良心理情绪提供了依据。
Objective To investigate the effect of motivational interviewing (MI) on anxiety and depression in patients with newly diagnosed lung cancer chemotherapy (chemotherapy). Methods From May 2015 to April 2016, patients undergoing primary chemotherapy for lung cancer admitted to the department after surgery were divided into MI group and control group by using digital random table method. The control group was given routine nursing care, including health education, psychological care and hospital follow-up. The MI group was given three motivational interviews and one phone follow-up intervention on the basis of routine nursing care to relieve anxiety and depression. Two groups of patients were admitted to hospital one month after chemotherapy with self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS) and Chinese version of the psychological pain thermometer (Distress Thermometer, DT). Results At admission, there was no significant difference in SAS, SDS and DT scores between the two groups (P> 0.05). At 1 month after chemotherapy, SAS, SDS and DT scores in MI group were relieved as compared with those at admission, the difference was statistically significant (P <0.05); SAS, SDS and DT scores in MI group were significantly lower than those in control group Significance (P <0.05). Conclusion MI can improve the anxiety and depression in patients with initial treatment of lung cancer chemotherapy, which provides a basis for the clinical staff to intervene in the treatment of patients with newly diagnosed lung cancer.